Loading
IDRx, a Boston company, developed IDRX-42, a pill aimed at the KIT gene changes that drive most gastrointestinal stromal tumours (GIST). GSK bought the company in 2025.
IDRx, Inc. was a Boston-based, clinical-stage company developing precision treatments for gastrointestinal stromal tumours. Its lead molecule, IDRX-42, is a highly selective KIT tyrosine kinase inhibitor being developed for first- and second-line treatment; GSK's announcement says about 80% of GIST cases are driven by KIT mutations and that IDRX-42 has shown activity against all key primary and secondary KIT mutations. GSK agreed on 13 January 2025 to buy IDRx for USD 1 billion upfront plus a possible USD 150 million regulatory milestone, and completed the acquisition on 24 February 2025.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · GSK's announcement of 13 January 2025, filed on a 6-K: USD 1 billion upfront with a potential additional USD 150 million success-based regulatory approval milestone; completion announced 24 February 2025 | 2025 | $1B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
IDRX-42 is an experimental small-molecule drug from GlaxoSmithKline in phase 3 trials for gastrointestinal stromal tumour, with its target not yet stated publicly.
Shares IDRX-42, Gastrointestinal stromal tumour (GIST), GSK.
Shares KIT, Gastrointestinal stromal tumour (GIST), Small-molecule kinase inhibitors.
Shares Gastrointestinal stromal tumour (GIST), Small-molecule kinase inhibitors.
Shares Gastrointestinal stromal tumour (GIST), Small-molecule kinase inhibitors.
Shares KIT, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/